NASDAQ: CRME TSX: COM
VANCOUVER, March 15 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) announced today that Doug Janzen, President and CEO, is scheduled to present an overview of Cardiome at the Barclays Capital 2011 Global Healthcare Conference on Wednesday, March 16, 2011 at 2:30pm Eastern (11:30am Pacific).
A live webcast of Mr Janzen's presentation can be accessed on Cardiome's website at www.cardiome.com. A replay of the webcast will be posted after the presentation and will be available until April 18, 2011.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.
Forward-Looking Statement Disclaimer
Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
"believe", "may", "plan", "will", "estimate", "continue", "anticipate",
"intend", "expect" and similar expressions. Such forward-looking
statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
events or developments, or industry results, to be materially different
from any future results, events or developments expressed or implied by
such forward-looking statements or information. Risks, uncertainties
and factors that could cause such actual events or results expressed or
implied by such forward-looking statements and information to differ
materially from any future events or results expressed or implied by
such statements and information include, but are not limited to, the
risks, uncertainties and factors related to the fact that: we, together
with our collaborative partners, may not be able to successfully
develop all or any of our current or future products and may not be
able to obtain regulatory approval in targeted indications for our
current or future products in all markets; we may not achieve or
maintain profitability; our future operating results are uncertain and
likely to fluctuate; we may not be able to raise additional capital as
and when required; we depend on our collaborative partners to perform
their obligations under licensing or other collaborative agreements; we
may not be successful in establishing additional corporate
collaborations or licensing arrangements; we may not be able to
establish marketing and sales capabilities and the costs of launching
our products may be greater than anticipated; any of our products that
obtain regulatory approval will be subject to extensive post-market
regulation that may affect sales, marketing and profitability; any of
our products that are successfully developed may not achieve market
acceptance; we rely on third parties for the continued supply and
manufacture of our products and have no experience in commercial
manufacturing; we may face unknown risks related to intellectual
property matters, including with respect to our ability to protect our
intellectual property; we face increased competition from
pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Securities and Exchange
Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to
place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary
statement. All forward-looking statements and information made herein
are based on our current expectations and we undertake no obligation to
revise or update such forward-looking statements and information to
reflect subsequent events or circumstances, except as required by law.
SOURCE Cardiome Pharma Corp.
